ADMA Biologics Inc
ADMA.OQ- Latest Trade
- trading higher1.96USD
- Change
- 0
- % Change
0.00%
- Day Range
- 1.92 - 2.02
- 52-Week Range
- 1.01 - 2.31
As of Jun 30 2022. Values delayed up to 15 minutes
- Previous Close
- 1.96
- Open
- 2.01
- Volume
- 726,696.00
- 3 Month Average Trading Volume
- 63.27
- Shares Out (Mil)
- 196.35
- Market Cap
- 396.63
- Forward P/E
- -6.41
- Dividend Yield
- -99,999.99
Key Statistics
1.5 mean rating - 2 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 4.22
- Price To Book (Quarterly)
- 3.12
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 109.05
- Long Term Debt/Equity (Quarterly)
- 109.05
- Return On Investment (TTM)
- -31.89
- Return On Equity (TTM)
- -28.79
2021 (millions USD)
About ADMA Biologics Inc
Company Information
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and markets specialty plasma-based biologics for the treatment and prevention of infectious diseases. It is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product candidates include BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates source plasma collection facilities in the United States. Its Plasma Collection Centers segment, provides a portion of its blood plasma for the manufacture of its products candidates.
Address
465 State Route 17, 65 Commerce WayHACKENSACK, NJ
07601
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Steven A. Elms
- Independent Chairman of the Board
- Adam S. Grossman
- President, Chief Executive Officer, Co-Founder, Director
- Jerrold B. Grossman
- Vice Chairman of the Board, Co-Founder
- Brian Lenz
- Chief Financial Officer, Executive Vice President
- Martha J. Demski
- Independent Director
- Bryant E. Fong
- Independent Director
- Lawrence P. Guiheen
- Independent Director
- Young T. Kwon
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,813.70 | -- |
| Copper | 694.25 | -- |
| Brent Crude Oil | 116.19 | 0.06%Negative |
| CBOT Soybeans | 1,671.00 | 0.19%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,818.83 | 0.07%Negative |
| Euro STOXX 50 | 3,514.32 | -- |
| FTSE 100 | 7,312.32 | 0.15%Negative |
| Nikkei 225 | 26,380.44 | 1.58%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes